Johnson & Johnson

NYSE:JNJ   2:08:38 PM EDT
164.65
-0.77 (-0.46%)
Products

Janssen - FDA Approves Expanded Pad Indication For Xarelto Plus Aspirin To Include Patients After LER Due To Symptomatic Pad

Published: 08/24/2021 15:20 GMT
Johnson & Johnson (JNJ) - FDA Approves Expanded Peripheral Artery Disease (pad) Indication for Xarelto® (rivaroxaban) Plus Aspirin to Include Patients After Lower-extremity Revascularization (ler) Due to Symptomatic Pad.
Janssen - FDA Approves Expanded Pad Indication for Xarelto Plus Aspirin to Include Patients After Ler Due to Symptomatic Pad.